Patient Centricity

The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality

Patient centricity: A defining imperative in healthcare As patient expectations evolve and regulatory bodies demand greater transparency, the pharmaceutical industry is undergoing a profound transformation in terms of patient centricity. Our latest white paper, “The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality,” explores how patient centricity has shifted from…...
Read More

Top Stories

Nelson memo

The Nelson Memo: Igniting a Global Open Data

The landscape of scientific research is undergoing a seismic...
Rare diseases

Rare Diseases – An Evolving Medical

A disease is considered rare when it affects fewer than 1 in...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Periodic Safety Update Report (PSUR) - Medical Device

Periodic Safety Update Report (PSUR): A Breakdown of MDCG 2022-21

A well-structured, clear, and concise PSUR enables a seamless notified body review. Read our key...
HEOR Pharma Payers

Didactic to Dynamic: Innovative Approaches to Deeper Payer Engagements

HEOR is a fast-evolving field. Feedback from payers can influence research plans and help create...
Medical Device Regulation

Clinical Evidence: How Much Is Enough?

Ensuring the safety and functionality of your medical device is vital. But how much clinical...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.